scholarly journals Corrigendum to: Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy

2021 ◽  
Author(s):  
Alberto Iannalfi ◽  
Emma D’Ippolito ◽  
Giulia Riva ◽  
Silvia Molinelli ◽  
Sara Gandini ◽  
...  
Skull Base ◽  
2005 ◽  
Vol 15 (S 2) ◽  
Author(s):  
Anthony Cheesman ◽  
H. Crockard ◽  
N. Plowman

Author(s):  
Daniela Schulz-Ertner ◽  
Christian P. Karger ◽  
Alexandra Feuerhake ◽  
Anna Nikoghosyan ◽  
Stephanie E. Combs ◽  
...  

2015 ◽  
Vol 24 (8) ◽  
pp. 528-534
Author(s):  
Azusa Hasegawa ◽  
Masashi Koto ◽  
Ryo Takagi ◽  
Kensuke Naganawa ◽  
Hiroaki Ikawa ◽  
...  

Skull Base ◽  
2009 ◽  
Vol 19 (01) ◽  
Author(s):  
Satoshi Takahashi ◽  
Takeshi Kawase ◽  
Kazunari Yoshida ◽  
Azusa Hasegawa ◽  
Jun-etsu Mizoe

2009 ◽  
Vol 151 (7) ◽  
pp. 759-769 ◽  
Author(s):  
Satoshi Takahashi ◽  
Takeshi Kawase ◽  
Kazunari Yoshida ◽  
Azusa Hasegawa ◽  
Jun-etsu Mizoe

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 339
Author(s):  
Giulia Buizza ◽  
Chiara Paganelli ◽  
Emma D’Ippolito ◽  
Giulia Fontana ◽  
Silvia Molinelli ◽  
...  

Skull-base chordoma (SBC) can be treated with carbon ion radiotherapy (CIRT) to improve local control (LC). The study aimed to explore the role of multi-parametric radiomic, dosiomic and clinical features as prognostic factors for LC in SBC patients undergoing CIRT. Before CIRT, 57 patients underwent MR and CT imaging, from which tumour contours and dose maps were obtained. MRI and CT-based radiomic, and dosiomic features were selected and fed to two survival models, singularly or by combining them with clinical factors. Adverse LC was given by in-field recurrence or tumour progression. The dataset was split in development and test sets and the models’ performance evaluated using the concordance index (C-index). Patients were then assigned a low- or high-risk score. Survival curves were estimated, and risk groups compared through log-rank tests (after Bonferroni correction α = 0.0083). The best performing models were built on features describing tumour shape and dosiomic heterogeneity (median/interquartile range validation C-index: 0.80/024 and 0.79/0.26), followed by combined (0.73/0.30 and 0.75/0.27) and CT-based models (0.77/0.24 and 0.64/0.28). Dosiomic and combined models could consistently stratify patients in two significantly different groups. Dosiomic and multi-parametric radiomic features showed to be promising prognostic factors for LC in SBC treated with CIRT.


Sign in / Sign up

Export Citation Format

Share Document